Summary powerpoint presentation of trial

Created using ChatSlide

This lecture explores bleeding risks in venous thromboembolism (VTE) management, focusing on the COBRRA trial. It examines therapeutic roles of Apixaban and Rivaroxaban, trial methodology, and clinically relevant outcomes influencing practice, including bleeding risks, mortality, and adherence. The session discusses subgroup findings, limitations, and strategic conclusions, highlighting Apixaban’s superior safety profile and implications for VTE treatment. Additionally, attendees will review...